Circulation · 1986 · 168 citations · 16 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyNeuropharmacologyPharmacodynamicsCardiovascular PharmacodynamicsCardiovascular PharmacologyCardiovascular PhysiologyCoronary Artery DiseaseHemodynamic PharmacologyVasoactive Drug TherapyMediatorsPharmacodynamics Of Cardiovascular DrugsPharmacology Of Serotonergic AgentsSerotonergic AgonistsSerotonin AgonistsSerotonin AntagonistsSerotonin PharmacodynamicsVasoactive Drug Mechanisms
The data obtained in this study demonstrate that the concentration of serotonin is markedly elevated (18- to 27-fold) at the site of a coronary arterial stenosis in open-chest, anesthetized dogs with cyclic flow variations. Cyclic flow variations in this experimental preparation were abolished by ketanserin, a 5-hydroxytryptamine antagonist, but serotonin concentration at the site of the coronary stenosis remained elevated. The intra-atrial administration of serotonin (0.16 to 1 mg/min) restored cyclic flow variations after they had been abolished by ketanserin. Taken together, these data suggest that serotonin may be one of the important mediators of cyclic flow variations in this experimental preparation.
16
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
J.E. Leysen, F. Awouters, Ludo Kennis et al. · Life Sciences · 1981 · 846 citations